MRK at a glance
Merck & Co. (MRK, SEC CIK 310158) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 18, 2026 and Form 4 insider filings as recently as November 16, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Merck & Co. (MRK) reported revenue of $65.0 billion (up 1.3% from FY2024) and net income of $18.3 billion. Diluted EPS was $7.28.
- As of September 30, 2026, 69 institutional investment managers tracked by SignalX reported holding Merck & Co. (MRK) shares worth $135.4 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by DeLuca Richard R. on November 12, 2026 of 58,185 shares at $148.01 per share.
- In the last 90 days, MRK insiders reported 0 open-market purchases ($0) and 1 open-market sale ($8.6M) on Form 4, a net sale of $8.6M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $65.0B
- +1.3% vs prior year
- Insiders · 90 days
- 0 buys · 1 sell
- Net −$8.6M
- 13F holders
- 69 funds
- $135.4B · −2 vs prior quarter
- Latest 8-K
- Nov 18, 2026
- Item 5.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Management Discussion & Analysis
- Revenue $65.0B in 2025, up 1% YoY (+2% ex-FX) from $64.2B; US sales +13% to $36.5B, international -11% to $28.5B
- Gross margin 74.8% vs 76.3% in 2024; GAAP EPS $7.28 vs $6.74; non-GAAP EPS $8.98 vs $7.65
- Best segment: Pharmaceutical (Keytruda/Keytruda Qlex $31.7B, +7%; Welireg +41%); worst: Vaccines, with Gardasil/Gardasil 9 -39% to $5.2B on China demand collapse
- Operating cash flow $16.5B (vs $21.5B in 2024); capex $4.1B; dividends $8.2B; buybacks $5.1B (~59M shares); quarterly dividend raised to $0.85/share
- Key risks: Keytruda IRA government price-setting effective 2029, Januvia/Janumet US exclusivity loss May/Jul 2026, $9.2B Cidara acquisition closing Jan 2026 with ~$9.0B R&D charge expected Q1 2026
Risk Factors
- IRA price setting: Keytruda (49% of total 2025 sales) expected selected by HHS in 2027, government price effective Jan 1, 2029, U.S. sales to decline materially
- Gardasil/Gardasil 9 China shipments paused since Feb 2025; local competitor's nine-valent HPV vaccine approved June 2025 for females 9-45 years
- Keytruda biosimilar competition expected Dec 2028 when primary compound patent expires, with European market exclusivity lost 2031
- Bridion loses U.S. exclusivity July 2026; Januvia/Janumet loses exclusivity May 2026; Company expects to lose "nearly all" U.S. Januvia/Janumet sales thereafter
- IRS examining 2017-2018 tax returns including TCJA one-time transition tax position; adverse outcome described as potentially material to cash flows
Business Overview
- Global pharma/animal health company; Pharmaceutical segment (89% of sales) anchored by Keytruda immunotherapy franchise generating $31.7B in FY2025
- Keytruda Qlex (subcutaneous pembrolizumab) launched in 2025; FDA-approved September 2025 across most adult solid tumor indications: new formulation extending franchise runway beyond 2028 Keytruda compound patent expiry
- Gardasil revenue collapsed to $5.2B from $8.6B (-39% YoY) driven by China market contraction; Winrevair (PAH) debuted at $1.4B vs zero in 2024, partially offsetting Gardasil decline
- ~75,000 employees globally as of Dec 31, 2025; US international sales mix shifted to 56% domestic / 44% international vs 50/50 in 2024, reflecting China Gardasil erosion
- December 2025: Merck signed a "Most-Favored-Nation" agreement with the US government; committing to direct-to-patient pricing, Medicaid discounts, and MFN-linked launch pricing for new products in exchange for a 3-year Section 232 tariff delay on manufacturing imports
AI summary of the MRK 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Revenue $18.1B, up 5% YoY from $17.3B, driven by oncology, cardiometabolic, respiratory, specialty and animal health
- Gross margin 72.9% vs 77.7% YoY, pressured by amortization, restructuring costs and Verona inventory step-up
- Best performer: Winrevair sales up 93%; worst: Lagevrio sales down 88% in the quarter
- Cash and investments $11.3B vs $15.5B at year-end; operating cash flow $15.8B vs $13.6B YoY
- Outlook: pricing pressure, generic competition and government cost containment expected to continue reducing sales and profits
AI summary of the MRK 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Thomas H. Glocer retiring from Merck’s Board at the 2027 Annual Meeting
- Departure not related to disagreements, reducing governance disruption and transition risk
Item EX-99.1: Item EX-99.1
- Thomas H. Glocer to retire from Merck’s Board at the May 2027 annual meeting
- Douglas M. Baker Jr. appointed independent lead director effective January 1, 2027
Item 2.02: Results of Operations and Financial Condition
- Third-quarter 2026 earnings announced in Merck’s October 29, 2026 press release
- Supplemental financial information provided in Exhibit 99.2 for investor review
Item EX-99.2: Item EX-99.2
- Q3 sales $18,085M, up 5%; pharmaceutical sales $16,268M, up 4%, while Animal Health rose 4% to $1,676M
- Keytruda sales fell 5% to $7,771M, offset by Keytruda Qlex $830M and Winrevair growth of 93% to $694M
Item EX-99.1: Item EX-99.1
- Q3 sales $18.1B, up 5%, led by KEYTRUDA $8.6B and WINREVAIR $694M, up 93%
- GAAP EPS $2.04, down 12%; non-GAAP EPS $2.49, down 3%, including $0.12 SciBrunch charge
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Paul J. Diaz elected to Merck’s Board effective November 1, 2026
- Diaz joins Audit Committee, strengthening board oversight of financial reporting and controls
Item EX-99.11: Item EX-99.11
- Paul J. Diaz joins Merck’s board effective November 1, 2026
- Board expands to 14 members, subject to shareholder election in May 2027
AI summaries of MRK 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for MRK
Don't miss the next MRK filing
- Alerts as it files. A push when MRK files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut MRK, by share count.
- Ask anything. An AI agent that reads every MRK filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| DeLuca Richard R. | M | Nov 12, 2026 | 58,185 | - |
| DeLuca Richard R. | M | Nov 12, 2026 | 58,185 | $77.62 |
| DeLuca Richard R. | Sell | Nov 12, 2026 | 58,185 | $148.01 |
| DIAZ PAUL J | A | Nov 1, 2026 | 613.073 | $149.52 |
| Seidman Christine E | A | Sep 30, 2026 | 55.915 | $145.31 |
| Karsanbhai Surendralal Lanca | A | Sep 30, 2026 | 111.83 | $145.31 |
| Coe Mary Ellen | A | Sep 30, 2026 | 206.455 | $145.31 |
| Guindo Chirfi | Sell | Aug 13, 2026 | 10,000 | $135.00 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $60.1B | $64.2B | $65.0B |
| Net Income | $365.0M | $17.1B | $18.3B |
| Net Margin | 0.6% | 26.7% | 28.1% |
| Balance Sheet | |||
| Total Assets | - | $117.1B | $136.9B |
| Equity | $37.6B | $46.3B | $52.6B |
| ROE | 1.0% | 37.0% | 34.7% |
| Per Share | |||
| EPS | $0.14 | $6.74 | $7.28 |
| Cash Flow | |||
| Operating CF | $13.0B | $21.5B | $16.5B |
| CapEx | $3.9B | $3.4B | $4.1B |
Source: XBRL data in Merck & Co. (MRK)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate MRK share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 69 | $135.40B |
| Q2 2026 | 71 | $123.99B |
| Q1 2026 | 70 | $117.04B |
| Q4 2025 | 68 | $101.02B |
| Q3 2025 | 71 | $83.32B |
| Q2 2025 | 71 | $76.78B |
| Q1 2025 | 69 | $66.08B |
| Q4 2024 | 64 | $61.79B |
- T. Rowe Price Group+8.09M (+44%)
- Goldman Sachs Group+2.00M (+9%)
- Citadel Advisors LLC+1.39M (+72%)
- Millennium Management+1.18M (+211%)
- BlackRock+1.07M (+0%)
- D.E. Shaw & Co−1.93M (-70%)
- Dimensional Fund Advisors−1.21M (-7%)
- JPMorgan Chase & Co−771.1K (-2%)
- Northern Trust−611.2K (-2%)
- Prudential Financial−414.7K (-22%)
- FMR LLC (Fidelity)−45.44M
- Equitable Holdings Inc−113.0K
- Northwest Bancshares, Inc.−53.4K
- Ally Financial Inc−35.0K
Source: 13F-HR filings on SEC EDGAR (aggregated from 553 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
MRK filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Nov 18, 2026 | - | Analysis | - |
| 4 | Nov 16, 2026 | - | - | - |
| 13F-HR | Nov 13, 2026 | Sep 30, 2026 | - | |
| 10-Q | Nov 4, 2026 | Sep 30, 2026 | Analysis | |
| 4 | Nov 3, 2026 | - | - | - |
| 8-K | Oct 29, 2026 | - | Analysis | - |
| 8-K | Oct 13, 2026 | - | Analysis | - |
| 4 | Oct 1, 2026 | - | - | - |
| 4 | Oct 1, 2026 | - | - | - |
| 4 | Oct 1, 2026 | - | - | - |
| 4 | Aug 13, 2026 | - | - | - |
| 4 | Aug 13, 2026 | - | - | - |
| 4 | Aug 12, 2026 | - | - | - |
| 4 | Aug 10, 2026 | - | - | - |
| 13F-HR | Aug 7, 2026 | Jun 30, 2026 | - | |
| 4 | Aug 7, 2026 | - | - | - |
| 4 | Aug 7, 2026 | - | - | - |
| 4 | Aug 7, 2026 | - | - | - |
| 10-Q | Aug 7, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 4, 2026 | - | Analysis | - |
| 4 | Jul 1, 2026 | - | - | - |
| 4 | Jul 1, 2026 | - | - | - |
| 4 | Jul 1, 2026 | - | - | - |
| 8-K | May 28, 2026 | - | Analysis | |
| 8-K | May 22, 2026 | - | Analysis |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
MRK SEC filings: frequently asked questions
Are MRK insiders buying or selling?
In the last 90 days, Merck & Co. (MRK) officers, directors and 10% owners reported no open-market purchases and 1 open-market sale worth $8.6 million by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold MRK stock?
As of September 30, 2026, the largest Merck & Co. (MRK) holders among the 13F filers tracked by SignalX were BlackRock ($33.1 billion), Vanguard Capital Management LLC ($23.5 billion), State Street Corp ($17.7 billion), Vanguard Portfolio Management LLC ($9.9 billion), Morgan Stanley ($7.0 billion). 13F-HR reports are filed up to 45 days after each quarter ends.
What was MRK's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Merck & Co. (MRK) reported revenue of $65.0 billion (up 1.3% from FY2024) and net income of $18.3 billion. Diluted EPS was $7.28. The figures come from the XBRL data in the 10-K.
What are the main risks in MRK's latest 10-K?
In the 10-K filed February 24, 2026, Merck & Co. (MRK) flagged: IRA price setting: Keytruda (49% of total 2025 sales) expected selected by HHS in 2027, government price effective Jan 1, 2029, U.S. sales to decline materially. Gardasil/Gardasil 9 China shipments paused since Feb 2025; local competitor's nine-valent HPV vaccine approved June 2025 for females 9-45 years. (AI summary of the Risk Factors section.)
What did MRK report in its latest 8-K?
Merck & Co. (MRK) filed an 8-K on November 18, 2026 reporting Item 5.02 (Departure/Appointment of Directors or Principal Officers). Thomas H. Glocer retiring from Merck’s Board at the 2027 Annual Meeting.
What are the latest MRK SEC filings?
Merck & Co. (MRK) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 18, 2026 and a Form 4 insider filing on November 16, 2026.
What is MRK's SEC CIK number?
Merck & Co. (MRK)'s SEC Central Index Key (CIK) is 310158. EDGAR lists every MRK filing under that number.
Ask anything about MRK
The research agent reads MRK's filings, financials, insider trades and 13F holders, then answers with sources.